The incidence of brain metastases in breast cancer according to molecular subtype and stage: a 10-year single institution analysis

Christopher Poletes, Bardia Amanirad, Anna T. Santiago,Michael Yan,Tatiana Conrad,Katarzyna J. Jerzak,David B. Shultz

Journal of Neuro-Oncology(2024)

Cited 0|Views4
No score
Abstract
Breast cancer (BC) is the second most common etiology of brain metastases (BrM). We aimed to examine the incidence of BrM among all BC patients presenting to a large tertiary cancer centre over one decade. We included all BC patients presenting consecutively between 2009 and 2019 and cross referenced that cohort to a radiotherapy database, identifying patients treated for BrM at any time following their initial presentation. Cumulative incidences (CI) of BrM diagnoses were calculated using death as a competing risk and compared using the Fine-Gray method. Overall survival was estimated using the Kaplan Meier method. We identified 12,995 unique patients. The CI of BrM in patients who initially presented with Stage 0–4 disease was 2.1
More
Translated text
Key words
Breast cancer,Brain metastases,HER2 +,ERBB2 +,Triple negative,Molecular subtype,Trastuzumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined